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We propose a combination of machine learning techniques to integrate predictive proﬁling from gene expression with
clinical and epidemiological data. Starting from BioDCV, a complete software setup for predictive classiﬁcation and fea-
ture ranking without selection bias, we apply semisupervised proﬁling for detecting outliers and deriving informative sub-
types of patients. During the proﬁling process, sampletracking curves are extracted, and then clustered according to a
distance derived from dynamic time warping. Sampletracking allows also the identiﬁcation of outlier cases, whose removal
is shown to improve predictive accuracy and stability of derived gene proﬁles. Here we propose to employ clinical features
to validate the semisupervising procedure. The procedure is demonstrated in the analysis of a liver cancer dataset of 213
samples described by 1993 genes and by pathological features.
 2007 Elsevier Inc. All rights reserved.
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Microarray and other high-throughput technologies are being extensively used to evaluate genetic markers
potentially associated with onset and progression of disease. To determine the role of diﬀerent genetic proﬁles
on disease outcomes, it is crucial to devise new machine learning methods supporting the identiﬁcation of pat-
terns from a variety of genomic, biological, and clinical data sources. In most cases, deciphering the physio-
logical basis of complex diseases requires to clarify the heterogeneity of the illness by subgrouping the disease
population [1], and possibly to exploit annotation data present in gene-centered corpora [2].
In the last few years, a growing interest has arises for integrating genomic and clinical data [3–5]. For
instance, a very recent work [6] in this ﬁeld proposes a strategy based on Bayesian networks to treat clinical
and microarray data on an equal footing. In this probabilistic strategy, the integration of the two data sources
may be obtained at diﬀerent levels of complexity to understand the underlying model structure and
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ranking process: instead, the clinical features are used downstream in the procedure to validate the biological
consistency of the resulting prediction. We ﬁrst search for a proﬁling process improved both in terms of pre-
dictive accuracy as well as of stability of the gene signature. Then we analyze the subtypes derived from the
expression data in conjunction with the available pathological information. In particular, we propose to
employ clinical features to validate the results of the semisupervised procedure.
We base this procedure on BioDCV (Biodata Distributed Complete Validation), a software setup for pre-
dictive molecular proﬁling. Complete validation is an experimental scheme for the correct assessment of pre-
dictive accuracy in gene expression studies. In order to control for selection bias [7], it requires intensive
resampling and replication of the classiﬁcation processes. To overcome computing limits of standard
resources, BioDCV was designed to implement complete validation schemes on distributed computing
resources such as clusters and virtual GRID facilities [8]. The proﬁles considered in this study are based on
the method recently introduced in [9] for semisupervised pattern discovery from functional genomics data.
The method has been proposed to obtain subtyping and outlier detection from diagnostic functions derived
from the complete validation scheme applied to a target classiﬁcation task.
As an example, we apply the BioDCV system to Liver cancer proﬁling, considering a dataset of relatively
large size and endowed with description of pathological features [10]. The dataset of Sese’s study includes
more than one hundred of positive samples of diﬀerent age, sex and previous exposure to diseases or physi-
ological states potentially correlated to liver cancer. In the case of the Sese dataset, the original target function
is the discrimination of liver cancer patients from control cases. Answering to this biological question is a rel-
atively easy task, on this dataset, as estimated predictive error is close to 3%. Questions such as subtyping for
response to treatment are typically much more complex to answer, and semisupervised learning has been pro-
posed in particular for predicting survival [11].
The structure of the paper is as follows. In Section 2, we describe ﬁrst the core classiﬁcation and feature
selection procedures used in the BioDCV system. In the same Section, we deﬁne the complete validation
schema, the semisupervised approach and the outlier detection strategy. In Section 3, we present the applica-
tion on the liver cancer dataset: classiﬁcation results, sampletracking analysis, outlier detection and stability of
obtained biomarkers are discussed, on both the complete and the shaved dataset. The integration with the clin-
ical features is then presented in the dedicated Section 3.3.
2. Methods
The study of gene expression patterns is expected to enable signiﬁcant advances in disease diagnosis and
prognosis. Generally, biomaterials (such as tissues) from diﬀerent phenotypes are analyzed for an automatic
discrimination based on their gene expression proﬁle, trying to highlight which are the most important fea-
tures (genes) supporting this classiﬁcation. Therefore, we need:
(i) a classiﬁer to train the model;
(ii) a ranking method to ﬁnd the more important genes;
(iii) a complete validation procedure to protect from selection bias in estimating predictive error and bio-
marker list.
In Section 2.1 we outline the selection bias problem, while in 2.2 and 2.3 we brieﬂy introduce SVM and
feature selection methods; in Section 2.4 we detail the employed procedure designed to avoid the selection bias.
In Section 2.5 we describe the procedure employed for the detection of subtypes and outlier removal. Clinical
features are then used to validate the results.
2.1. Selection bias
As reported in [12], a serious procedural problem aﬀects a number of results in the literature in gene pro-
ﬁling methodology. Initial studies on microarray data proposed classiﬁcation models deﬁned by very few
genes and resulting in negligible or zero error rates. As discussed in [13,14], the problem is that the feature-
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mates of the prediction error. This ﬂaw in methodology is know as ‘‘selection bias’’. While the problem
may be reproduced with any wrapper algorithm, selection bias is a speciﬁc risk for recursive gene selection
procedures, and especially for systems based on the RFE–SVM pair.
2.2. Support vector machines
Support vector machines (SVM) [15], which are considered a performing classiﬁcation method for gene-
expression data, were soon embedded with feature selection procedures. A backward selection approach like
the recursive feature elimination (RFE) procedure is often adopted with SVM [16] (see Section 2.3).
Let F: X! {1,1} be an unknown function and let D ¼ fpi  ðxi; yiÞgNi¼1 be a set of training examples,
where xi 2 X and yi 2 {1,1}. In order to approximate the function F the following algorithm can be
considered:
• Choose a Mercer kernel, i.e., a continuous, symmetric and positive deﬁnite function K : X  X ! R. Exam-
ples of such Mercer kernels are the Linear kernel K(x,x 0) = hx,x 0i, the Gaussian kernel Kðx; x0Þ ¼ ekxx0k2=r
and the polynomial kernel K(x,x 0) = 1 + hx,x 0id. Observe that for any given x, the function of a single var-
iable KxðxÞ ¼ Kðx; xÞ can be deﬁned.
• Choose the regularization parameter C 2 (0, +1).
• Deﬁne fC : X ! R as follows:fCðxÞ ¼
XN
i¼1
ciKxiðxÞ; ð1Þwhere ci = yiai and the vector a is the solution to the quadratic programming problem:max
a2RN
PN
i¼1
ai  12
PN
i;j¼1
yiyjaiajKðxi; xjÞ
subject to 0 6 ai 6 C i ¼ 1; . . . ;N :
8><
>:• Deﬁne the classiﬁer ~f CðxÞ ¼ signðfCðxÞÞ. This is the parametric approximation of the unknown function
F(x).
Typically, the regularization parameter C is optimized by employing statistical model selection procedures,
e.g., cross-validation. In the linear case, approximation (1) reduces to fC(x) = hw,xi + b.2.3. Feature selection
The recursive feature elimination (RFE) is a well-known feature selection method for support vector
machines ﬁrstly introduced in [16]. This method has been evaluated in experimental analysis and it is consid-
ered eﬀective for gene selection and classiﬁcation on microarrays. The idea is to deﬁne the importance of a
feature for SVM in terms of its contribution to a cost function J(a). At each step of the RFE procedure, a
SVM is trained on the given data set, J is computed and the feature that less contributes to J is discarded.
In the case of linear SVM, the diﬀerence due to the elimination of the ith feature isdJðiÞ ¼ w2i ;
and in the non-linear case isdJðiÞ ¼ 1
2
atZa 1
2
atZðiÞa;where Zi,j = yiyjK(xi,xj).
The heavy computational cost of RFE is a function of the number of original variables, because a SVM
must be trained each time a variable is removed. The elimination of a single variable at each step (as in the
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are generally similar and concentrated nearby zero. The removal of a group of variables at every loop repre-
sents a feasible approach, and it was suggested in [16].
Entropy-based recursive feature elimination (E-RFE), is a non-parametric procedure for gene ranking,
which accelerates – without reducing accuracy – the standard recursive feature elimination (RFE) method
for SVM. This strategy was introduced in [17]. The aim of the E-RFE procedure is to provide a more ﬂexible
feature elimination mechanism in which the ranking is obtained by discarding groups of genes which contrib-
ute least to the SVM classiﬁer. In E-RFE we cautiously discard, according to the entropy of the weight dis-
tribution, several (possibly many) genes at each step to drive the weight distribution in a high-entropy
structure of a few equally important variables.
2.4. The complete validation system: BioDCV
The complete validation methodology involves three diﬀerent procedures. The method is composed of three
main procedures, organized as in Fig. 1:
ONF (optimal number of features); the procedure computes the optimal number of features (n*).
OFS-M (optimal feature set-model); the procedure trains the model with the ﬁrst n* ranked features. The
model is tested on a test portion.
VAL (validation); the procedure validates the OFS-M procedure over B replicates according to a resam-
pling scheme.
In summary, given a dataset (matrix of gene expressions), the VAL procedure analyses B replicated exper-
iments (runs) according to a resampling scheme. At each run, a training/test split (TRb,TSb) is created and
only the training portion is used by OFS-M procedure. The ONF procedure identiﬁes an optimal feature sub-
set and the corresponding model is constructed in OFS-M procedure. The model is tested on the test portion
TSb (unused in the development of the model). Thus an average test (predictive) error can be computed from
the B test error values TEb in the VAL procedure.
More in detail, given a training set TRb, the ONF procedure is applied to select the optimal number of
features based on a ranking method. A resampling procedure is iterated K times, producing each time a
ðTRbk ;TSbk Þ split of TRb. A feature ranking is applied to TRbk . Then, n subsets are created with the ﬁrst Fi
features of the feature list (i.e., F1 = 1,F2 = 5,F3 = 10, . . .,Fn = 1000). Therefore, for each k a model family
(Mbki; i ¼ 1; . . . ; n) is produced, one for each increase of Fi. The Mbki models are evaluated on the TSbk test
data, computing TEbki test errors, and we obtain the average error curve TE
b
i ¼ 1K
PK
k¼1TE
b
ki. An exponential
ﬁt is applied to TEbi , and the n
* value leading to saturation in terms of the exponential curve is returned as
the ONF result.DATA
SET
Run 1
Run 2
Run b
Run B
OFS-M ONF
R
esam
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TRb
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Fig. 1. The complete validation setup.
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mal feature set OFS of size n* is selected. Based on ONF procedure, a model Mb is developed by a suitable
learning method. The accuracy of OFS-M is validated by the VAL procedure on B replicated experiments
(runs) using a resampling scheme. The model with n* features is tested on the test set, in order to minimize
risk of data overﬁtting, obtaining a TEb error. The procedure returns the expected test errorFATE ¼ 1
B
XB
b¼1
TEb:Together with the average test error, a bootstrap conﬁdence interval at 95% is usually computed for each
point throughout all the replicated experiments.
2.4.1. BioDCV implementation
The BioDCV system (http://biodcv.itc.it) implements the above described complete validation setup. Bio-
DCV is portable from single workstations to local Linux clusters and virtual GRID facilities. It is written in C
and interfaced with the SQLite database management library (http://www.sqlite.org). Support to concurrent
access and transactions is used to store and manage results and parameters during the learning, tuning and
evaluation tasks, which may be replicated for up to a few millions of models in a distributed environment.
The system is distributed under GPL.
The main engine of BioDCV is the libml library, a C toolbox for learning problems, including the support
vector machine (SVM) applied in this study. BioDCV runs also within the Egrid (http://www.egrid.it) com-
putational infrastructure, based on Globus/EDG/LCG2 middleware and integrated as an independent virtual
organization within the Grid.it, the INFN production grid. Part of the computation described in this paper
was performed on a local computing facility (an Open Mosix cluster of 26 bi-processors units and 1 data
server).
2.5. Semisupervised proﬁling and outlier shaving
The semisupervised procedure [9] implemented in BioDCV is based on an analysis of the eﬀect of the fea-
ture selection and ranking process for each individual sample. Given a complete validation setup (such as the
one described in Section 2.4), for each sample s, we count the number N(s) of runs in which s is extracted in a
test set and, for each feature step size fs also the number of timesW(s, fs) that s is wrongly classiﬁed when in the
test set. The sequences Es(fs) =W(s, fs)/N(s) may be studied as an estimate of the classiﬁcation error as a func-
tion of the size of the feature set. We call Es(fs) the sampletracking proﬁle (curve) of the sample: easily clas-
siﬁable points correspond to curves reaching zero, while curves not far from the no-information error rate (theNumber of features
E(
S)
0.0
0.5
1.0
1 5 50 150 500 1993
Number of features
E(
S)
0.0
0.5
1.0
1 5 50 150 500 1993
ig. 2. Examples of sampletracking proﬁles from the liver cancer dataset (see Section 3): easy point (left) and outlier (right).
Fig. 3. Block diagram of the BioDCV proﬁling. To identify subgroups and study the association with clinical features, BioDCV is run
twice, ﬁrst on the complete dataset and then on its shaved version (outliers removed).
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error zone indicates a typical outlier behaviour. Examples for the liver cancer dataset used in this study are
shown in Fig. 2.
The response to the supervised classiﬁcation task is then used to drive a secondary unsupervised pattern
discovery process. Similar classiﬁcation responses may be aggregated by a hierarchical clustering technique,
which we apply with a (1,2,1) dynamic time warping (DTW) distance. Aach and Church [18] proposed
DTW for use on gene time series data in expression studies. This distance is more suited than Euclidean metric
in curves comparison, because it takes into account morphology instead of just evaluating the pointwise dis-
tance of the vectors.
The described methodology is summarized in Fig. 3. BioDCV is ﬁrst applied to the entire data set and the
sampletracking proﬁles are analyzed for outlier detection and removal. Then, BioDCV is again applied on the
outlier shaved dataset. The clusters of the sampletracking proﬁles resulting from the semisupervised proce-
dure, deﬁning potential subtypes, are ﬁnally compared with pathological features to detect common relevant
patterns.
3. Results
We applied the semi-supervised proﬁling procedures to the liver cancer dataset originally analyzed in [10].
The dataset consists of 213 cases described by 1993 values of ATAC-PCR gene expression. The basic task is
the predictive discrimination of the 107 samples extracted from tumors (liver cancer patients) from the 106
control samples. Several clinical features are available and of interest for the pathology, as displayed in Table
1. The pathological information is encoded as boolean variables, i.e., by binary features.
3.1. Semisupervised analysis
Following the pipeline in Fig. 3, the BioDCV system was applied to the complete liver cancer dataset. Lin-
ear SVM models were used for classiﬁcation, with regularization parameter C = 100. Classiﬁcation was cou-
pled to the E-RFE ranking method, reverting to standard RFE in the last 100 steps. Average test error (ATE)
results are reported in Table 2 for increasing number of features. Results are obtained by averaging over 400
replicated experiments.
The sampletracking curves (examples are shown in Fig. 4) were then obtained and hierarchically clustered
with respect to DTW distance by the hclust algorithm (average link) from the stats package in the R sta-
tistical system [19].
Table 1
Summary of pathological features and their binary encoding
Abbr. Feature Value Binary
V-B Hepatitis B Positive 1
Negative 0
V-C Hepatitis C Positive 1
Negative 0
A Age Over 65 years old 1
Not over 65 years old 0
S Sex Male 1
Female 0
C-A Child score A High 1
Low 0
C-B Child score B High 1
Low 0
Cir Cirrhosis Present 1
Absent 0
Table 2
Predictive error (ATE: average test error) for the liver cancer dataset with the full set of 213 samples and after outlier removal (shaved)
Feat. Complete dataset Shaved dataset
ATE CI ATE CI
1 27.7 (26.9, 28.6) 24.3 (23.6, 25.0)
2 24.3 (23.5, 25.3) 20.4 (19.5, 21.6)
3 21.8 (21.0, 22.8) 15.4 (14.6, 16.4)
4 18.4 (17.8, 19.1) 11.4 (10.9, 11.9)
5 16.6 (16.1, 17.3) 9.9 (9.4, 10.4)
10 12.7 (12.3, 13.1) 5.9 (5.6, 6.2)
20 8.9 (8.6, 9.3) 3.4 (3.2, 3.7)
50 5.8 (5.5, 6.1) 1.8 (1.6, 2.0)
100 4.8 (4.5, 5.0) 1.5 (1.3, 1.6)
500 3.4 (3.1, 3.6) 1.5 (1.3, 1.7)
1000 3.1 (2.9, 3.4) 1.5 (1.4, 1.7)
1993 3.2 (3.0, 3.5) 1.5 (1.3, 1.7)
Studentized bootstrap conﬁdence intervals (CI .95 level) are included.
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derived from their sampletracking patterns and further conﬁrmed by the cluster structure.
The BioDCV system was applied again after removing the outliers. The original and new accuracy scores
are compared in Table 2: for every feature set size, the ATE values improve after removing the outliers. In
particular, a minimum error is achieved at 100 features (ATE = 1.5%). With only 20 genes, the
ATE = 3.4% is obtained on the shaved dataset, while 500 genes were required for the same ATE on the com-
plete dataset. The dendrogram obtained by clustering the sampletracking curves of the cancer cases is shown
in Fig. 5. The rightmost arm of the dendrogram (denoted by C1) is particularly well separated from the other
positive samples, providing indication for further analysis (see Section 3.3).
3.2. Stability analysis
We compared the ranked gene lists before and after the removal of outliers (stability analysis). For the two
cases, the genes ranked in the top k positions in the 400 lists were listed and ordered for decreasing multiplicity
of extractions (Exts). The lists computed proﬁling the shaved dataset are shorter: for instance, at k = 5 and
k = 20, respectively, 129 versus 228 genes and 330 versus 427 genes were extracted at least once. The top genes
extracted in the shaved dataset are consistently more important for classiﬁcation. In fact, the best genes are
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Fig. 4. Sampletracking proﬁles for disease (red) and control (blue) samples from the liver cancer dataset. Sample 40 and sample 47 are two
outliers. (For better interpretation of the ﬁgure in colour, the reader is referred to the web version of this article.)
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the best ranked 10 genes is detailed in Table 3 for k = 5 and k = 20.
We then compared the distribution of the mutual distances among the lists (1993 genes, Canberra distance)
in the unshaved and shaved versions of the dataset (Fig. 6). The distribution of the distances in the reduced
dataset has lower mean (437.9 versus 487.7) and standard deviation (41.4 versus 42.8), indicating that the 400
lists of the shaved dataset are mutually more similar than those of the complete dataset.
In summary, the structure of the two sets of ranked lists are diﬀerent. The analysis points out that the out-
lier shaving has improved both ATE and the stability of the features (genes) that are relevant for the classi-
ﬁcation problem.
3.3. Integration with clinical data
The semisupervised procedure in Section 3.1 evidenced an interesting subgroup of 8 liver cancer samples
(C1). As a case study, C1 was then analyzed in terms of the relationships between pathological features
and gene expressions. In Fig. 7, the structure of C1 is paired with the clinical data.
81
a
41
a
40
a
12
7a 75
a
52
a
30
0
64
a
13
0a
68
a
22 70
a
29
a
10
5a
54
51
a
67
a
89
a
79
a 88 1
24
96
a
87
a
63
a
97
a
62 86
a
49
a
30
1a 2
0
66 11
8 3
02 24
12
8a
80
a
12
3
11
6
47
a
45
a
93
a
98
a
19
13
2
10
6a
50
a
82
a 21
a
92
a
83
a
11
2
42
a
11
9a
72
a
57
a
48
a 25
36
a
58
a
69
a
10
3
12
1
12
2a
30 95 14
4a
56
a
90
a 5
5a
59
a
99
a
43
a
37
a
44
a
85
10
0a
11
1
14
3a
61
a
17 27
a
12
5
84
10
9
12
0
10
4a 13
7
91
a
14 11
7
13 33
0.
00
0
0.
00
2
0.
00
4
0.
00
6
0.
00
8
Positive
H
ei
gh
t
Fig. 5. Dendrogram of the DTW-distance clustering from semisupervised analysis of the liver cancer cases (after outlier removal).
Table 3
Summary of the properties of the best 10 genes extracted in the top k positions (k = 5, k = 20) in both experiments
Pos. Gene Exts. Mean SD Pos. Gene Exts. Mean SD
k = 5  complete k = 5  shaved
1 GS1686 120 1.8 1.2 1 GS3244 217 2.8 1.1
2 GS201 90 3.3 1.3 2 GS6094 196 3 1.2
3 GS11954 87 2.3 1.4 3 GS1686 155 2.2 1.4
4 GS1324 85 2.5 1.4 4 GS11954 120 2.8 1.3
5 GS6094 78 2.4 1.3 5 GS2303 106 2.3 1.4
6 GS3244 74 2.7 1.3 6 GS10759 86 3.5 1.2
7 GS6487 70 2.4 1.2 7 GS12544 78 2 1.4
8 GS10588 56 2.1 1.1 8 GS201 75 3.6 1.2
9 GS11601 56 2.7 1.3 9 GS2131 67 2.5 1.4
10 GS5927 52 2.8 1.4 10 GS2954 61 3.6 1.1
k = 20  complete k = 20  shaved
1 GS201 260 9 5.5 1 GS3244 356 5.6 4.4
2 GS1324 212 8.4 5.8 2 GS6094 336 5.9 4.3
3 GS1686 204 6.2 6.1 3 GS201 276 8.9 4.8
4 GS3244 198 8.7 5.9 4 GS1686 264 5.8 5.2
5 GS6094 194 8.7 6.1 5 GS10759 248 8.6 5.1
6 GS11601 194 9.7 5.9 6 GS1710 235 10.1 5.4
7 GS11954 187 7.5 5.9 7 GS11954 232 7.2 5.5
8 GS3097 163 11.3 4.9 8 GS2954 232 9.6 4.9
9 GS2375 152 10.8 4.8 9 GS1324 214 10.4 6
10 GS10424 145 11.2 5.2 10 GS2303 212 7.5 6.2
66 S. Paoli et al. / Internat. J. Approx. Reason. 47 (2008) 58–69The last two rows in the table (Fig. 7, right) provide a comparison of incidence of the pathological feature
in the cluster and in the subset Pos of all the 98 liver cancer cases. All subjects in C1 are positive to Virus C and
negative to Virus B. They belong mostly to the elderly group. Note that they are all males but for sample 116:
this subject is detected as a singleton by the DTW-based clustering focused on this subgroup.
It is interesting to backtrack to the gene expressions for the samples in the identiﬁed subgroup. In particular
we may study the best ranked genes according the BioDCV proﬁling for C1 in comparison to the dataset strat-
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Fig. 6. Histogram and density plots of the mutual Canberra distances among the 400 gene lists obtained on the complete dataset SS1
(solid line) and on the outlier shaved dataset SS2 (dashed line).
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Fig. 7. The dendrogram of the C1 subgroup (left) and table of clinical features of the corresponding samples (right): sample label (n),
virus-type b (v-b) and c (v-c), age > 65 (a), sex (s), child score a (c-a) and b (c-b), and presence of cirrhosis (cir). The last two lines show
percentage of values equal to 1 in the C1 subgroup and in the set Pos of all the cancer samples (shaved dataset).
S. Paoli et al. / Internat. J. Approx. Reason. 47 (2008) 58–69 67iﬁcation. In Fig. 8 the expressions of 5 of the best 20 genes (top-20 list) are considered aggregating on control
cases (blue), cancer cases (red), C1 (orange), and those (yellow) sharing some of the same clinical features
(VB = 0, VC = 1, S = 1) of the samples belonging to C1. The genes GS3244, GS3309, GS6487, GS11817,
GS189 provide a better separation between C1 and controls than for all cancer cases. Finally, the subset
deﬁned by the clinical feature pattern is closer to C1 than the set of all cancer cases for all these top ranked
genes.
4. Conclusions
In this study, we have shown that the high-throughput structure of complete validation schemes for gene
proﬁling may support new modes of semisupervised analysis based on the concept of sampletracking pro-
ﬁles. With the availability of covariate features of pathological relevance, there is a challenging opportunity
for subtype discovery methods, with applications for the search of biomarkers in a very interesting class of
studies.
Gene Expression
–2 –1 0 1 2
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Fig. 8. Comparing the expressions of 5 top ranked genes for diﬀerent subgroups: C1 (orange), all liver cancer (red, class 1), those sharing
some a pattern of pathological features with C1 (yellow), and controls (blue, class-1). (For better interpretation of the ﬁgure in colour, the
reader is referred to the web version of this article.)
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